List of Rykindo drug patents

Rykindo is owned by Shandong Luye.

Rykindo contains Risperidone.

Rykindo has a total of 5 drug patents out of which 0 drug patents have expired.

Rykindo was authorised for market use on 13 January, 2023.

Rykindo is available in for suspension, extended release;intramuscular dosage forms.

Rykindo can be used as treatment of schizophrenia in adults.

The generics of Rykindo are possible to be released after 10 April, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406161 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(8 years from now)

US10098882 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(8 years from now)

US9532991 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(8 years from now)

US9446135 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(8 years from now)

US11110094 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(8 years from now)

Do you want to check out RYKINDO patents from before 2022?

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 13 January, 2023

Treatment: Treatment of schizophrenia in adults

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in